• 제목/요약/키워드: Upper Gastrointestinal bleeding

검색결과 62건 처리시간 0.025초

Von Recklinghausen disease병 환아에서 상부위장관 출혈로 발현한 위의 신경섬유종 1례 (Gastric neurofibroma in von Recklinghausen disease : a cause of upper gastrointestinal bleeding)

  • 권보상;심정옥;서정기;양혜란;고재성;정성은;김우선;강경훈
    • Clinical and Experimental Pediatrics
    • /
    • 제49권2호
    • /
    • pp.203-207
    • /
    • 2006
  • 위장관계의 신경섬유종의 발생빈도는 드물다고 알려져 있다. 저자들은 제1형 신경섬유종증의 15세 남자 환아에서 상부위장관 출혈로 발현한 위에 생기는 신경섬유종을 내시경 및 상부위장관 조영술을 통해 진단을 내리고, 수술적 제거를 시행하였던 1례를 경험하였기에 문헌 고찰과 함께 보고하는 바이다.

상부 위장관 출혈 (Upper Gastrointestinal Bleeding in Children)

  • 김준성
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제11권sup2호
    • /
    • pp.29-34
    • /
    • 2008
  • 소아에서의 급성 상부 위장관 출혈은 흔하지는 않지만 잠재적으로 심각한 위험을 초래할 수 있는 문제이다. 상부 위장관 출혈의 원인은 환아의 연령에 따라 다양하기 때문에 소아 환자를 평가할 때는 각 연령대 별로 흔한 특정 원인들을 미리 염두에 두는 것이 필요하다. 환자의 상태가 위중할 때는 신속한 병력 청취와 활력 징후 측정, 정맥 확보 및 특정 검사 등이 빠른 시간내에 이루어지는 것이 중요하다. 응급 상황에서는 기도 확보, 호흡, 순환 등 초기 심폐소생술을 먼저 시행한 후에 자세한 병력 청취, 신체 검사와 함께 상부 위장관 출혈을 일으킨 기저 질환을 확인하기 위하여 더 자세한 특수한 진단적 검사 등이 필요하고, 이를 근거로 각각의 원인에 따른 적절한 치료가 시행되어야 한다.

  • PDF

상부위장관 출혈 환자에서 위험의 계층화와 이에 따른 치료 전략 (Risk Stratification for Patients with Upper Gastrointestinal Bleeding)

  • 이봉은
    • 대한상부위장관⦁헬리코박터학회지
    • /
    • 제18권4호
    • /
    • pp.225-230
    • /
    • 2018
  • Upper gastrointestinal (GI) bleeding (UGIB) is the most common GI emergency, and it is associated with significant morbidity and mortality. Early identification of low-risk patients suitable for outpatient management has the potential to reduce unnecessary costs, and prompt triage of high-risk patients could allow appropriate intervention and minimize morbidity and mortality. Several risk-scoring systems have been developed to predict the outcomes of UGIB. As each scoring system measures different primary outcome variables, appropriate risk scores must be implemented in clinical practice. The Glasgow-Blatchford score (GBS) should be used to predict the need for interventions such as blood transfusion or endoscopic or surgical treatment. Patients with GBS ${\leq}1$ have a low likelihood of adverse outcomes and can be considered for early discharge. The Rockall score was externally validated and is widely used for prediction of mortality. The recently developed AIMS65 score is easy to calculate and was proposed to predict in-hospital mortality. The Forrest classification is based on endoscopic findings and can be used to stratify patients into high- and low-risk categories in terms of rebleeding and thus is useful in predicting the need for endoscopic hemostasis. Early risk stratification is critical in the management of UGIB and may improve patient outcome and reduce unnecessary health care costs through standardization of care.

New Oral Anticoagulants를 복용하는 환자들에서 위장관 출혈의 위험인자 (Risk Factors of Gastrointestinal Bleeding in Patients Receiving New Oral Anticoagulants)

  • 이주엽
    • 대한상부위장관⦁헬리코박터학회지
    • /
    • 제18권4호
    • /
    • pp.219-224
    • /
    • 2018
  • New oral anticoagulants (NOACs) are now widely used for the prevention and treatment of venous thrombosis, and for the prevention of stroke and systemic embolism in patients with atrial fibrillation. As compared with warfarin, NOACs have the advantage of rapid onset of action and less drug interaction. However, they carry a higher risk of gastrointestinal (GI) bleeding than warfarin. The risk of GI bleeding in patients using NOACs varies according to the type and dose of the drug. By contrast, apixaban and edoxaban are reported to carry similar risks as warfarin, and the risks with dabigatran and rivaroxaban are higher than that with warfarin. In patients using NOACs, old age, impaired renal function, impaired liver function, concurrent use of antiplatelet agents, and nonsteroidal anti-inflammatory drugs are considered major risk factors of GI bleeding, and gastroprotective agents such as histamine-2 receptor antagonist and proton pump inhibitor have preventive effects. To prevent GI bleeding associated with NOACs, the characteristics of each NOAC and the risk factors of bleeding should be recognized.

소화성 궤양 출혈의 내시경 치료 (Endoscopic Hemostatic Treatment of Peptic Ulcer Bleeding)

  • 최연화;박준철
    • 대한상부위장관⦁헬리코박터학회지
    • /
    • 제18권4호
    • /
    • pp.235-241
    • /
    • 2018
  • Peptic ulcer bleeding is a common complication of peptic ulcer disease and the most common cause of upper gastrointestinal bleeding. Despite advances in drug usage and endoscopic modalities, no significant improvement is observed in the mortality rate of bleeding ulcers. The purpose of this review is to discuss various endoscopic hemostatic methods to treat peptic ulcer bleeding. Endoscopic hemostatic techniques can be classified into injection, mechanical, electrocoagulation, hemostatic powder, and endoscopic Doppler-guided hemostatic therapies (the last mentioned being a newly developed technique). Endoscopic hemostasis can be performed as mono or combination therapy using the aforementioned methods. Endoscopic hemostasis is the most important treatment for patients with peptic ulcer bleeding. Endoscopists should consider the treatment approach for peptic ulcer bleeding based on patient characteristics, the size and shape of the lesion, the endoscopist's expertise, and the resources and circumstances at each hospital. Follow-up studies are needed to evaluate the efficacy of newly developed hemostatic powder therapy and endoscopic Doppler-guided hemostasis.

Preclinical study of a novel ingestible bleeding sensor for upper gastrointestinal bleeding

  • Kimberly F. Schuster;Christopher C. Thompson;Marvin Ryou
    • Clinical Endoscopy
    • /
    • 제57권1호
    • /
    • pp.73-81
    • /
    • 2024
  • Background/Aims: Upper gastrointestinal bleeding (UGIB) is a life-threatening condition that necessitates early identification and intervention and is associated with substantial morbidity, mortality, and socioeconomic burden. However, several diagnostic challenges remain regarding risk stratification and the optimal timing of endoscopy. The PillSense System is a noninvasive device developed to detect blood in patients with UGIB in real time. This study aimed to assess the safety and performance characteristics of PillSense using a simulated bleeding model. Methods: A preclinical study was performed using an in vivo porcine model (14 animals). Fourteen PillSense capsules were endoscopically placed in the stomach and blood was injected into the stomach to simulate bleeding. The safety and sensitivity of blood detection and pill excretion were also investigated. Results: All the sensors successfully detected the presence or absence of blood. The minimum threshold was 9% blood concentration, with additional detection of increasing concentrations of up to 22.5% blood. All the sensors passed naturally through the gastrointestinal tract. Conclusions: This study demonstrated the ability of the PillSense System sensor to detect UGIB across a wide range of blood concentrations. This ingestible device detects UGIB in real time and has the potential to be an effective tool to supplement the current standard of care. These favorable results will be further investigated in future clinical studies.

소화성 궤양 출혈의 약물 치료 (Pharmacological Treatment for Peptic Ulcer Bleeding)

  • 마대원;김병욱
    • 대한상부위장관⦁헬리코박터학회지
    • /
    • 제18권4호
    • /
    • pp.231-234
    • /
    • 2018
  • Peptic ulcer bleeding (PUB) is the most common cause of non-variceal upper gastrointestinal bleeding, and its frequency has been declining over the past decades. However, mortality from PUB persists, and it is still a serious challenge in clinical practice. Although endoscopic intervention is the basic treatment modality for PUB, pharmacological therapy is an important adjunct. The emergence of proton pump inhibitors (PPIs) enables maintenance of intragastric pH >6, which greatly helps in the treatment of PUB. Continuous intravenous infusion of high-dose PPI reduces the re-bleeding rate, thereby helping avoid additional surgery in patients with high-risk stigmata. Moreover, administration of PPIs prior to endoscopy may reduce the need for additional endoscopic intervention. Recently introduced gastric acid suppressants, such as potassium-competitive acid blockers, have shown promising results in further treatment of PUB.

Availability of Blood Urea Nitrogen/Creatinine Ratio in Gastrointestinal Bleeding with Melena in Children

  • Kim, Kyu Seon;Kang, Chan Ho;Kim, Jae Young
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제18권1호
    • /
    • pp.30-38
    • /
    • 2015
  • Purpose: The aims of our study were to evaluate the blood urea nitrogen to creatinine ratio (BUN/Cr ratio) for distinguishing between an upper and lower gastrointestinal bleeding (GIB), and differentiating between the two most common causes of upper gastrointestinal bleeding (UGIB) presenting with melena in children. Methods: Retrospective data of patients with GIB presenting with melena were analyzed. The data from 60 cases were reviewed including demographics, laboratory findings, diagnostic modalities and results, treatments, and transfusions. Results: Among the 60 cases, UGIB and lower gastrointestinal bleeding (LGIB) were found in 35 cases (58.3%) and 14 cases (23.3%), respectively. The two common causes of UGIB were varices (37.1%), and peptic ulcer diseases (PUD) (31.4%). The BUN/Cr ratio of 30 or greater was higher in UGIB than LGIB (odds ratio [OR], 6.9; 95% confidence interval [95% CI], 1.3-37.2). In UGIB, the BUN/Cr ratio of the varices group was higher than that of the PUD group (p=0.015). The OR for the BUN/Cr ratio appeared as 1.2 per unit increase in the varices group than the PUD group (95% CI, 1.03-1.3). There was no difference between the PUD group and Meckel's diverticulum group. Conclusion: The BUN/Cr ratio was not uneven in differentiating UGIB from LGIB of children with melena in our study. This suggests that BUN/Cr ratio should be interpreted carefully.